Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep28 | Adrenal and Cardiovascular Endocrinology | ECE2020

The role of cytotoxic chemotherapy in adjuvant treatment of radically resected adrenocortical carcinoma

Kimpel Otilia , Shokry Daniel Bedrose Sara , Megerle Felix , Daher Marilyne , Kroiss Matthias , Amir Habra Mouhammed , Fassnacht Martin

Background: The recent ESE-ENSAT guidelines on adrenocortical carcinoma (ACC) indicated new treatment options for patients with “high risk for recurrence” as one of the major research topics for the field. However, since almost no data were available on the use of cytotoxic drugs in an adjuvant setting, no clear recommendation could be given. Here we report our experience with adjuvant platin-based therapy since 2002 at the University of Würzburg and MD Anders...

ea0070aep30 | Adrenal and Cardiovascular Endocrinology | ECE2020

Excess glucocorticoid activity may suppress tumor immune activity in adrenocortical carcinoma

Greenstein Andrew , Amir Habra Mouhammed , Mura Marzena , Biernat Paweł , Piatek Marek J , Grauer Andreas , Peacock Shepherd Stacie

Introduction: Excess glucocorticoid (GC) activity has been implicated in the pathophysiology of multiple cancer types. For instance, approximately half of adrenocortical carcinoma (ACC) patients exhibit excess GC (GC+). This provides a unique opportunity to study correlates of GC activity, such as a possible suppression of tumor immune response and immune checkpoint inhibitor (ICI) efficacy due to the broad immunosuppressive effects of GC. ACC multi-omics data can be used ...

ea0089c43 | Clinical – Surgery/Applied Pathology | NANETS2022

Post-Operative Biochemical Surveillance Thresholds Can be Used to Monitor for Sympathetic Pheochromocytoma/Paraganglioma Recurrence and Metastasis

S Lui Michael , B Fisher Sarah , G Grubbs Elizabeth , D Perrier Nancy , G Waguespack Steven , Varghese Jeena , A Habra Mouhammed , Jimenez Camilo , H Graham Paul

Background: Sympathetic pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine tumors associated with excess catecholamine production. Routine biochemical and imaging surveillance to monitor for recurrence and metastasis is recommended. However, there is limited data describing optimal surveillance approaches and post-operative biochemical thresholds for detecting recurrences or metastases. This study sought to correlate biochemical and imaging surveillance with ...

ea0098c5 | Clinical – Chemo/SSA/Biologics | NANETS2023

A phase 2 clinical trial of cabozantinib in patients with unresectable and progressive metastatic pheochromocytoma or paraganglioma: The NATALIE trial

Jimenez Camilo , Habra Mouhammed A. , Campbell Matthew T. , Tamsen Gina , Cruz-Goldberg Damaris , Long James , Bassett Roland , Dantzer Robert , Balderrama Vania , Varghese Jeena , Waguespack Steven , Lu Yang

Background: Metastatic pheochromocytomas and paragangliomas are orphan neuroendocrine tumors. 50% of these tumors are associated with germline mutations of the SDHB gene. SDHB related pheochromocytomas and paragangliomas and many apparently sporadic tumors exhibit abnormal angiogenesis. This trial assessed the efficacy and safety of Cabozantinib, a potent, antiangiogenic, tyrosine kinase inhibitor. Methods: The Natalie trial is a single arm phase 2 clini...

ea0098c31 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

High-specific-activity iodine-131-meta-iodo-benzylguanidine for the treatment of advanced pheochromocytoma and paraganglioma: a real-world study

Al-Ward Ruaa , Balderrama Brondan Vania , Sawani Sahar , Bassett Roland , Xu Guofan , Waguespack Steven G. , Varghese Jeena , Amir Habra Mouhammed , Lu Yang , Jimenez Camilo

Background: Metastatic pheochromocytomas and paragangliomas are rare neuroendocrine tumors with limited treatment options. We studied the efficacy and safety of off-label High-Specific-Activity I-131-meta-iodobenzylguanidine (HSA-I-131-MIBG) in routine clinical practice. Methods: This is a retrospective cohort study. The primary endpoint is objective response rate (ORR) as per RECIST v1.1. Secondary endpoints are blood pressure control, safety, overall a...